{"id":"NCT02792231","sponsor":"Novartis Pharmaceuticals","briefTitle":"Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.","officialTitle":"A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08-26","primaryCompletion":"2019-07-10","completion":"2020-10-22","firstPosted":"2016-06-07","resultsPosted":"2020-10-19","lastUpdate":"2021-11-22"},"enrollment":955,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Scelrosis"],"interventions":[{"type":"DRUG","name":"Ofatumumab subcutaneous injection","otherNames":[]},{"type":"DRUG","name":"Teriflunomide-matching placebo capsules","otherNames":[]},{"type":"DRUG","name":"Teriflunomide capsule","otherNames":[]},{"type":"DRUG","name":"Matching placebo of ofatumumab subcutaneous injections","otherNames":[]}],"arms":[{"label":"OMG 20 mg","type":"EXPERIMENTAL"},{"label":"TER 14 mg","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis","primaryOutcome":{"measure":"Annualized Relapse Rate (ARR)","timeFrame":"Baseline up to 2.5 years","effectByArm":[{"arm":"OMB 20 mg","deltaMin":0.1,"sd":null},{"arm":"TER 14 mg","deltaMin":0.25,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":178,"countries":["United States","Argentina","Australia","Austria","Belgium","Bulgaria","Canada","Croatia","Czechia","Finland","France","Germany","Hungary","India","Italy","Latvia","Lithuania","Mexico","Norway","Peru","Poland","Portugal","Russia","Slovakia","South Africa","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39018512","37606897","35266417","32757523"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":42,"n":481},"commonTop":["Injection related reaction","Injection related reaction","Nasopharyngitis","Nasopharyngitis","Headache"]}}